

**Advanced Enzyme Technologies Ltd.**

CIN: L24200MH1989PLC051018

Sun Magnetica, 'A' wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)-400 604, India

Tel: +91-22-4170 3200, Fax: +91-22-2583 5159

Email: info@advancedenzymes.com, www.advancedenzymes.com

February 05, 2022

**BSE Limited**

P. J. Towers,

Dalal Street,

Mumbai- 400 001

**Scrip Code-540025**

**National Stock Exchange of India Limited**

Exchange Plaza, Plot No. C/1,

G Block Bandra-Kurla Complex,

Bandra (E) Mumbai- 400 051

**Trading Symbol-ADVENZYMES**

Dear Sir/Madam,

**Subject: Outcome of Board Meeting held on February 05, 2022**

**Ref: ISIN: INE837H01020**

With reference to the notice of Board Meeting dated January 28, 2022, we hereby inform that the Board of Directors at its Meeting held on February 05, 2022 (commenced at 10:55 A.M. and concluded at 11:30 A.M.) has *inter alia*, approved the following:

- Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2021.
- Allotment of 9,200 Equity Shares of face value of Rs. 2/- at an exercise price of Rs. 60/- per share pursuant to exercise of options under the Employees Stock Option Scheme, 2015 (amended).

In view of the above, the following documents are enclosed:

- Unaudited Financial Results (Standalone & Consolidated) for the quarter and nine months ended December 31, 2021 along with the Limited Review report issued by MSKA & Associates, Statutory Auditors of the Company as an Annexure.

The aforesaid un-audited Financial Results along with Limited Review Report are also being uploaded on the website of the Company, i.e. [www.advancedenzymes.com](http://www.advancedenzymes.com)

This is for your information and for public at large.

Thanking you,

Yours faithfully,

**For Advanced Enzyme Technologies Limited**



**Sanjay Basantani**

**Company Secretary and Head - Legal**

Encl.: As above



**Independent Auditor's Review Report on Consolidated Unaudited Quarterly and year to date financial results of the Group, pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**The Board of Directors  
Advanced Enzyme Technologies Limited**

1. We have reviewed the accompanying statement of consolidated unaudited financial results of Advanced Enzyme Technologies Limited ('the Holding Company'), its subsidiaries, (the Holding Company and its subsidiaries together referred to as the 'Group') for the quarter ended December 31, 2021 and the year to-date results for the period from April 01, 2021 to December 31, 2021 ('the Statement'), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Regulations'). This statement is the responsibility of the Holding Company's Management and has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the statement based on our review.
2. This Statement has been prepared by the Holding Company's Management in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



# MSKA & Associates

Chartered Accountants

4. This Statement includes the results of the following entities:

Sr. No	Name of the Company	Relationship with the Holding Company
1	Advanced Bio-Agro Tech Limited	Subsidiary
2	Advanced Enzytech Solutions Limited	Wholly owned subsidiary
3	Advanced Enzymes USA, Inc. ('AEU')	Wholly owned subsidiary
4	Advanced Supplementary Technologies Corporation	Wholly owned subsidiary of AEU
5	Dynamic Enzymes, Inc	Wholly owned subsidiary of AEU
6	Cal India Foods International ('CAL')	Wholly owned subsidiary of AEU
7	Enzyme Innovation, Inc	Wholly owned subsidiary of CAL
8	JC Biotech Private Limited	Subsidiary
9	Scitech Specialities Private Limited	Subsidiary (w.e.f. 11 January 2021)
10	Advanced Enzymes (Malaysia) Sdn. Bhd	Wholly owned subsidiary
11	Advanced Enzymes Europe B.V. ('AEEBV')	Wholly owned subsidiary
12	Evoxx Technologies GmbH	Wholly owned subsidiary of AEEBV

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 & 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement is prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of four subsidiaries included in the consolidated unaudited financial results, whose interim financial results reflect total revenues of Rs. 353.44 Mn and Rs. 1,187.96 Mn, total net profit after tax of Rs. 44.32 Mn and Rs. 116.90 Mn and total comprehensive income of Rs. 43.70 Mn and Rs. 116.04 Mn, for the quarter ended December 31, 2021 and for the period from April 01, 2021 to December 31, 2021, respectively, before giving effect to the consolidation adjustments, as considered in the statement. These interim financial results have been reviewed by other auditors whose reports have been furnished to us and our conclusion on the Statement in so far



# MSKA & Associates

Chartered Accountants

relates to the amounts and disclosures included in respect of these subsidiaries, is solely based on the report of such other auditors and procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

7. The consolidated unaudited financial results includes the interim financial results of three subsidiaries which have not been reviewed by their auditors, whose interim financial results reflect total revenue of Rs. 37.01 Mn and Rs. 82.24 Mn, total net loss after tax of Rs. (15.87) Mn and Rs. (31.76) Mn and total comprehensive loss of Rs. (15.87) Mn and Rs. (31.79) Mn for the quarter ended December 31, 2021 and for the period from April 01, 2021 to December 31, 2021, respectively, before giving effect to the consolidation adjustments, as considered in the statement. According to the information and explanations given to us by the management, these interim financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

8. The unaudited financial results of the Group for the quarter and nine month ended December 31, 2020, included in the Statement, were reviewed by predecessor auditor whose report dated February 12, 2021 expressed an unmodified conclusion on those unaudited financial results.

The financial information of the Group for the year ended March 31, 2021 included in the Statement, were audited by predecessor auditor whose report dated May 29, 2021 expressed an unmodified opinion on those audited financial information.

Our conclusion is not modified in respect of these matters.

**For M S K A & Associates**  
Chartered Accountants  
ICAI Firm Registration No.105047W

**Amrish Vaidya**  
Partner  
Membership No.: 101739  
UDIN: 22101739AAMBFM4821

Place: Mumbai  
Date: 05 February, 2022



**Statement of unaudited consolidated financial results for the quarter and nine months ended 31 December 2021**

(₹ in million except per share data)

Particulars	Quarter ended			Nine months ended		Year ended
	31-Dec-21 Unaudited	30-Sep-21 Unaudited	31-Dec-20 Unaudited	31-Dec-21 Unaudited	31-Dec-20 Unaudited	31-Mar-21 Audited (Revised) (Refer note iv)
1 Revenue from operations	1,335.58	1,270.77	1,377.38	3,976.49	3,686.25	5,018.41
2 Other Income (refer note vi)	12.06	8.99	13.48	30.38	71.64	88.47
3 <b>Total Income (1+2)</b>	<b>1,347.64</b>	<b>1,279.76</b>	<b>1,390.86</b>	<b>4,006.87</b>	<b>3,757.89</b>	<b>5,106.88</b>
4 <b>Expenses</b>						
(a) Cost of materials consumed	366.18	291.78	285.64	960.34	704.13	1001.78
(b) Purchases of stock-in-trade	0.15	0.51	0.28	0.66	0.28	0.28
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(56.21)	(46.01)	4.14	(180.25)	(17.67)	(11.64)
(d) Employee benefits expense	254.02	256.86	213.73	780.29	638.86	871.07
(e) Finance costs (including exchange difference)	3.16	3.40	3.25	11.12	11.67	15.94
(f) Depreciation and amortisation expense	88.21	86.01	65.01	259.07	200.23	286.48
(g) Other expenses	280.90	274.77	209.74	804.54	594.39	841.66
<b>Total Expenses</b>	<b>936.41</b>	<b>867.32</b>	<b>781.79</b>	<b>2,635.77</b>	<b>2,131.89</b>	<b>3,005.57</b>
5 <b>Profit before exceptional item and tax (3-4)</b>	<b>411.23</b>	<b>412.44</b>	<b>609.07</b>	<b>1,371.10</b>	<b>1,626.00</b>	<b>2,101.31</b>
6 Exceptional item	-	-	-	-	-	-
7 <b>Profit before tax (5-6)</b>	<b>411.23</b>	<b>412.44</b>	<b>609.07</b>	<b>1,371.10</b>	<b>1,626.00</b>	<b>2,101.31</b>
8 Tax expense						
Current tax	119.06	119.33	142.00	398.68	443.31	579.56
Deferred tax charge / (credit)	6.62	(9.59)	24.04	(13.02)	6.02	8.89
<b>Total tax expense</b>	<b>125.68</b>	<b>109.74</b>	<b>166.04</b>	<b>385.66</b>	<b>449.33</b>	<b>588.45</b>
9 <b>Net profit for the period (7-8)</b>	<b>285.55</b>	<b>302.70</b>	<b>443.03</b>	<b>985.44</b>	<b>1,176.67</b>	<b>1,512.86</b>
10 <b>Other comprehensive income</b>						
A (i) Items that will not be reclassified to profit or loss						
Remeasurements of defined benefit liability/(asset)	(0.86)	(0.62)	(0.74)	(6.57)	(1.71)	1.55
(ii) Income tax related to items that will not be reclassified to profit or loss	0.23	0.19	0.21	1.70	0.51	(0.41)
B (i) Items that will be reclassified to profit or loss						
Exchange differences in translating financial statements of foreign operations	(4.22)	(20.85)	(29.06)	51.32	(108.58)	(100.44)
(ii) Income tax related to items that will be reclassified to profit or loss	-	-	-	-	-	-
<b>Total Other comprehensive income</b>	<b>(4.85)</b>	<b>(21.28)</b>	<b>(29.59)</b>	<b>46.45</b>	<b>(109.78)</b>	<b>(99.30)</b>
11 <b>Total comprehensive income (9+10)</b>	<b>280.70</b>	<b>281.42</b>	<b>413.44</b>	<b>1,031.89</b>	<b>1,066.89</b>	<b>1,413.56</b>
12 <b>Net profit attributable to:</b>						
Shareholders of the Company	274.84	296.98	430.88	951.50	1,145.22	1,459.32
Non-controlling interest	10.71	5.72	12.15	33.94	31.45	53.54
13 <b>Other comprehensive income attributable to:</b>						
Shareholders of the Company	(4.68)	(21.28)	(29.63)	46.52	(110.08)	(99.77)
Non-controlling interest#	(0.17)	0.00	0.04	(0.07)	0.30	0.47
14 <b>Total comprehensive income attributable to:</b>						
Shareholders of the Company	270.17	275.70	401.24	998.03	1,035.14	1,359.55
Non-controlling interest	10.53	5.72	12.20	33.86	31.75	54.01
15 <b>Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)</b>	<b>223.58</b>	<b>223.56</b>	<b>223.45</b>	<b>223.58</b>	<b>223.45</b>	<b>223.46</b>
16 <b>Other equity</b>						<b>9,485.92</b>
17 <b>Earnings Per Share of ₹ 2 each (not annualized)</b>						
(a) ₹ (Basic)	2.46	2.66	3.86	8.51	10.25	13.07
(b) ₹ (Diluted)	2.45	2.65	3.85	8.50	10.24	13.04

# Figures are below Rs 0.01 Million, hence disclosed as Rs 0.00



Sanjay K. Karm



**Advanced Enzyme Technologies Limited**

CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.

Tel No:91-22-41703220 Fax No: +91-22-25835159

Website: www.advancedenzymes.com, Email Id :sanjay@advancedenzymes.com

**Notes:**

(i) The above unaudited consolidated financial results include the financial results of Advanced Enzyme Technologies Limited (the "Company" or the "Holding Company") and the financial results of the subsidiary companies, Advanced Bio-Agro Tech Limited (India), Advanced Enzytech Solutions Limited (India), JC Biotech Private Limited (India), Scitech Specialities Private Limited (India) (w.e.f. 11 January 2021), Advance Enzymes USA, Inc. (U.S.A.), Cal India Foods International (U.S.A.), Advanced Supplementary Technologies Corporation (U.S.A.), Enzyme Innovation, Inc. (U.S.A.), Dynamic Enzymes, Inc. (U.S.A.), Advanced Enzyme (Malaysia) Sdn. Bhd. (Malaysia), Advanced Enzymes Europe B.V. (Netherlands) and Evoxx Technologies GmbH (Germany). The Holding Company and its subsidiary companies constitute the "Group".

(ii) The above unaudited consolidated financial results of the Group were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 5 February 2022. The above result have been subjected to 'limited review' by the statutory auditors of the Company and they have expressed an unmodified opinion. The limited review report will be filed with stock exchanges and will be available on the Company's website. The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

(iii) Effective 18 August 2021, the Company has acquired additional stake of 15% in its subsidiary JC Biotech Private Limited for consideration of Rs 211.25 million. Post this additional acquisition the Company holds 85% stake in the subsidiary. On account of acquisition of additional stake of 15% by the Company in JC Biotech Private Limited Non-controlling interest has been reduced by Rs. 123.67 million and adjusted Rs. 87.58 million in other equity. Impact of additional stake of 15% acquired in subsidiary JC Biotech Private Limited is summarised as below-

Particulars	₹ in million
(A) Consideration paid to acquire additional 15% stake	211.25
(B) Value of 15% non-controlling interest acquired	123.67
(C) Adjusted in other equity (A-B)	87.58

(iv) On 11 January 2021, the Group completed the acquisition of 51% of the paid up equity share capital in SciTech Specialities Private Limited ("SSPL") for a total consideration of Rs 316.26 million. As of 31 March 2021 the Group has accounted for the acquisition on provisional basis and finalised the purchase price allocation for the acquisition in the quarter ended on 30 September 2021 and accordingly, revised the provisions amounts of goodwill of Rs. 13.54 million. The Group on finalising of purchase price allocation has recognised fair value of Net Assets acquired of Rs. 320.00 million resulting in Capital reserve of Rs. 3.74 million. Also, the figures for the year ended 31 March 2021, quarter ended 30 September 2021 and quarter ended 31 December 2021, which includes figures for SSPL from the period 11 Jan 2021 to 31 March 2021, 1 July 2021 to 3 September 2021 and 1 October 2021 to 31 December 2021 respectively, are not comparable with the previous corresponding periods. As required by Ind AS 103- Business Combination, the Group has revised relevant period presented in these financial results to give impact of PPA adjustments after the date of acquisition and same is summarised as below:

**Impact on Consolidated Statement of Profit and Loss due to finalisation of purchase price allocation-**

(₹ in million)

Particulars	Year ended 31.03.2021
Total expenses*	2.40
Profit before tax	(2.41)
Profit after tax	(1.78)
Net profit for the period attributable to:	
- Equity shareholders of the Company	(2.66)
- Non-controlling interest	0.88
Basic earning per share	(0.02)
Diluted earning per share	(0.02)

\*includes depreciation and amortisation and other expenses

(v) The Group operates only in one business segment viz. 'manufacturing and sales of enzymes'.

(vi) Other income for the nine months ended 31 December 2020 and year ended 31 March 2021 includes Rs. 39.83 million of grant received from the Government of United States of America ("USA") by subsidiaries Cal India Foods International (U.S.A.), Advanced Supplementary Technologies Corporation (U.S.A.) and Enzyme Innovation, Inc. (U.S.A.) under CARES Act ("Act") as Paycheck Protection Program.

(vii) The Company has allotted 13,175 equity shares during the quarter ended 31 December 2021 and 63,050 equity shares during the nine months then ended to employees under the 'AETL Employee Stock Option Scheme 2015' ("AETL ESOS 2015").

(viii) The Group has considered internal and external information while assessing recoverability of its assets disclosed in the financial statement upto the date of approval of these financial results by the Board of Directors. Based on such assessment and considering the current economic indicators, the Group expects to recover the carrying amount of these assets. The Group has also considered the impact of COVID-19 on the business for the foreseeable future and has concluded that the Group has sufficient resources to continue as a going concern. The impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the Group will continue to closely monitor any material changes to future economic conditions.

(ix) Previous period/ year amounts have been regrouped/ reclassified wherever necessary.

Place: Thane

Dated: 5 February 2022



By Order of the Board of Directors

For Advanced Enzyme Technologies Limited

CIN No.: L24200MH1989PLC051018

M.M. Kabra

Wholetime Director

DIN : 00148294



**Independent Auditor's Review Report on unaudited quarterly and year to date standalone financial results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**The Board of Directors  
Advanced Enzymes Technologies Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Advanced Enzyme Technologies Limited ('the Company') for the quarter ended December 31, 2021, and the year to-date results for the period April 01, 2021 to December 31, 2021 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Regulation'). This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to express a conclusion on the statement based on our review.
2. This Statement has been prepared by the Company's Management in accordance with the recognition and measurement principles laid down in Ind AS 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether standalone financial results are free of material misstatements. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone financial results prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India, has not disclosed the information required to be



# MSKA & Associates

Chartered Accountants

HO  
602, Floor 6, Raheja Titanium  
Western Express Highway, Geetanjali  
Railway Colony, Ram Nagar, Goregaon (E)  
Mumbai 400063, INDIA  
Tel: +91 22 6831 1600

disclosed in terms of the Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. The unaudited financial results of the Company for the quarter and nine months ended December 31, 2020, included in the Statement, were reviewed by predecessor auditor whose report dated February 12, 2021 expressed an unmodified conclusion on those unaudited financial results.

The financial information for the year ended March 31, 2021 included in the Statement, were audited by predecessor auditor whose report dated May 29, 2021 expressed an unmodified opinion on those audited financial information.

Our conclusion is not modified in respect of these matters.

For M S K A & Associates  
Chartered Accountants  
ICAI Firm Registration No.105047W

Amrish Vaidya  
Partner  
Membership No.: 101739  
UDIN: 22101739AAMBOC9700

Place: Mumbai  
Date: 05 February, 2022



**Statement of unaudited standalone financial results for the quarter and nine months ended 31 December 2021**

(₹ in Million except per share data)

Particulars	Quarter ended			Nine months ended		Year ended
	31-Dec-21 Unaudited	30-Sep-21 Unaudited	31-Dec-20 Unaudited	31-Dec-21 Unaudited	31-Dec-20 Unaudited	31-Mar-21 Audited
1 Revenue from operations	643.87	649.11	791.45	2,020.50	2,128.65	2,834.73
2 Other Income	10.66	19.02	17.74	39.11	42.39	68.23
3 <b>Total Income (1+2)</b>	<b>654.53</b>	<b>668.13</b>	<b>809.19</b>	<b>2,059.61</b>	<b>2,171.04</b>	<b>2,902.96</b>
4 <b>Expenses</b>						
(a) Cost of materials consumed	258.22	294.19	280.20	808.51	701.22	950.34
(b) Purchases of stock-in-trade	-	-	-	-	-	-
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	10.24	(67.82)	25.50	(65.92)	9.10	12.74
(d) Employee benefits expense	90.94	94.16	85.52	296.84	258.18	342.34
(e) Finance costs (including exchange difference)	0.27	0.08	0.15	0.43	0.75	0.84
(f) Depreciation and amortisation expense	24.68	22.91	22.24	70.27	64.97	89.32
(g) Other expenses	152.43	152.16	131.38	428.42	373.22	523.10
<b>Total expenses</b>	<b>536.78</b>	<b>495.68</b>	<b>544.99</b>	<b>1,518.55</b>	<b>1,407.44</b>	<b>1,918.68</b>
5 <b>Profit before exceptional item and tax (3-4)</b>	<b>117.75</b>	<b>172.45</b>	<b>264.20</b>	<b>541.06</b>	<b>763.60</b>	<b>984.28</b>
6 Exceptional item	-	-	-	-	-	-
7 <b>Profit before tax (5-6)</b>	<b>117.75</b>	<b>172.45</b>	<b>264.20</b>	<b>541.06</b>	<b>763.60</b>	<b>984.28</b>
8 <b>Tax expense</b>						
Current tax	30.57	44.80	51.45	140.51	193.62	248.44
Deferred tax charge/(credit)	(0.52)	(0.76)	9.58	(1.04)	12.26	25.72
<b>Total tax expense</b>	<b>30.05</b>	<b>44.04</b>	<b>61.03</b>	<b>139.47</b>	<b>205.88</b>	<b>274.16</b>
9 <b>Net profit for the period (7-8)</b>	<b>87.70</b>	<b>128.41</b>	<b>203.17</b>	<b>401.59</b>	<b>557.72</b>	<b>710.12</b>
10 <b>Other comprehensive income</b>						
A (i) Items that will not be reclassified to Profit or Loss						
Remeasurements of defined benefit liability/(asset) #	0.00	-	(1.10)	(5.33)	(3.29)	(0.39)
(ii) Income tax related to items that will not be reclassified to Profit or Loss #	0.00	-	0.32	1.34	0.96	0.10
B (i) Items that will be reclassified to Profit or Loss	-	-	-	-	-	-
(ii) Income tax related to items that will be reclassified to Profit or Loss	-	-	-	-	-	-
<b>Total Other comprehensive income</b>	<b>0.00</b>	<b>-</b>	<b>(0.78)</b>	<b>(3.99)</b>	<b>(2.33)</b>	<b>(0.29)</b>
11 <b>Total comprehensive income (9+10)</b>	<b>87.70</b>	<b>128.41</b>	<b>202.39</b>	<b>397.60</b>	<b>555.39</b>	<b>709.83</b>
12 Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	223.58	223.56	223.45	223.58	223.45	223.46
13 Other equity	-	-	-	-	-	4,131.00
14 <b>Earnings Per Share of ₹ 2 each (not annualized)</b>						
(a) ₹ (Basic)	0.78	1.66	1.82	3.59	4.99	6.36
(b) ₹ (Diluted)	0.78	1.66	1.82	3.59	4.99	6.35

# Figures are below Rs 0.01 Million, hence disclosed as Rs 0.00



W. W. Karm



**Advanced Enzyme Technologies Limited**

CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.

Tel No: 91-22-41703220 Fax No: +91-22-25835159

Website: www.advancedenzymes.com, Email Id :sanjay@advancedenzymes.com

**Notes:**

(i) The above standalone financial results of the Advanced Enzyme Technologies Limited ('the Company') were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 5 February 2022. The above results have been subjected to 'limited review' by the statutory auditors of the Company and they have expressed an unmodified opinion. The limited review report will be filed with stock exchanges and will be available on the Company's website. The above results has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies in India.

(ii) The Company operates only in one business segment viz. 'manufacturing and sales of enzymes'.

(iii) The Company has allotted 13,175 equity shares during the quarter ended 31 December 2021 and 63,050 equity shares during the nine months then ended to employees under the 'AETL Employee Stock Option Scheme 2015' ("AETL ESOS 2015").

(iv) Effective 18 August 2021, the Company has acquired additional stake of 15% in its subsidiary JC Biotech Private Limited for a consideration of Rs 211.25 million. Post this additional acquisition the Company holds 85% stake in the subsidiary.

(v) The Company has considered internal and external information while assessing recoverability of its assets disclosed in the financial statement upto the date of approval of these financial results by the Board of Directors. Based on such assessment and considering the current economic indicators, the Company expects to recover the carrying amount of these assets. The Company has also considered the impact of COVID-19 on the business for the foreseeable future and has concluded that the Company has sufficient resources to continue as a going concern. The impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the Company will continue to closely monitor any material changes to future economic conditions.

(vi) Previous year / period amounts have been regrouped / reclassified wherever necessary.



By Order of the Board of Directors  
For Advanced Enzyme Technologies Limited  
CIN: L24200MH1989PLC051018

*M. M. Kabra*

**M. M. Kabra**  
Wholetime Director  
DIN : 00148294

Place: Thane  
Dated: 5 February 2022